MTOR and B-cell chronic lymphocytic leukemia: ADZ8055 was a dual mTOR kinase inhibitor with inhibition of both mTORC1 and mTORC2 that preferentially decreased cell viability of poor prognostic CLL subsets like with del (11q) or del (17p).